Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: OncoDNA, Interpace Diagnostics, CeCaVa, and More

NEW YORK (GenomeWeb) – OncoDNA said this week that new guidelines from the Spanish Society of Pathology and the Spanish Society of Medical Oncology now endorse genomic testing to identify cancers of unknown primary origin using tools like OncoDNA's OncoDEEP product: a combined DNA and protein assay performed on solid tumor samples.

The company presented data at the annual congress of the Spanish Society of Medical Oncology last month showing that OncoDEEP could be used to identify the origins of a tumor in more than 80 percent of cases and could detect potentially actionable mutations in more than 60 percent of cases.


Interpace Diagnostics reported this week that it has entered into an agreement with Piedmont Healthcare, Georgia's largest healthcare system, enabling all physicians in the Piedmont Healthcare Network to use the company's PancraGen molecular pancreatic cancer risk classifier for patients with indeterminate pancreatic cysts or other pancreaticobiliary lesions. Interpace recently announced an expansion of the applications for PancraGen to include biliary strictures and solid lesions.


Medical technology and pharmaceutical manufacturer B. Braun Melsungen and CeGaT this week announced the creation of a joint venture called CeCaVa GmbH & Co. to develop individualized vaccines to treat diseases, particularly tumorous diseases. CeCaVa, based in Tübingen, Germany stands for Center for Cancer Vaccines. CeGaT will contribute its expertise in genetic tumor diagnostics. Aesculap AG, a subsidiary of B. Braun Melsungen, will provide operational support.


Premaitha this week said it has signed a new partnership agreement between its Yourgene Bioscience division and an unspecified clinical research organization in Taiwan. Under the terms of the partnership, Yourgene will provide genetic testing services using NGS technology on patient samples gathered by the partner for the purpose of research into early-stage cancer screening. The collaborators anticipate the project will also have additional phases. The initial phase is anticipated to generate approximately $1 million of revenues over the next six to 12 months, Premaitha said.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.